4 news items
Lisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic Cancer
LSTA
20 May 24
solid tumors and other major diseases. Lisata's lead product candidate
Lisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024
LSTA
2 May 24
solid tumors and other major diseases. Lisata's lead product candidate
Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu's Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
LSTA
23 Apr 24
major diseases. Lisata's lead product candidate
Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events
LSTA
3 Apr 24
and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Lisata's lead product candidate
- Prev
- 1
- Next